STAT+: Hospitals sue – again – to halt Trump administration’s 340B rebate pilot

The American Hospital Association is challenging a federal plan to change how certain hospitals receive drug discounts. Instead of getting discounts upfront, hospitals would initially pay market prices and later apply for rebates. The dispute matters because hospitals may need substantial cash to buy medicines before receiving any savings.

The AHA says the government failed to accurately account for those added costs. Its lawsuit points to more than 2,400 comments submitted to the Health Resources and Services Administration. Hospitals reportedly described the model’s potential impact in detailed terms, including what the lawsuit calls a catastrophic effect.

This is the AHA’s second lawsuit over the idea. The expanded pilot is scheduled to begin January 1, 2027, and would cover 25 widely used, costly Medicare drugs. The case could determine whether the rebate approach proceeds and whether hospitals must change how they finance these purchases.

The 340B drug discount program lets eligible health care organizations obtain certain outpatient medicines at reduced prices. Congress created it to help providers with limited resources serve vulnerable patients and communities. The article focuses on hospitals and does not provide a complete list of participating organizations or eligibility requirements.

In practical terms, a participating hospital can use drug savings to support its broader mission. That may help it maintain services, assist patients with limited means, or manage expensive treatments. The central issue in this case is whether those savings arrive before or after the hospital pays for the medicine.

The lawsuit concerns a proposed change, not the program’s basic purpose. The rebate model would replace upfront discounts with later payments for selected drugs. The pilot’s effects would therefore depend on hospitals’ ability to finance purchases and receive rebates promptly. The article does not specify which patients would be affected first.

The expanded rebate pilot is scheduled to begin January 1, 2027. It would target 25 drugs covered under Medicare. The article describes them as among the costliest and most widely used medicines, making the pilot significant for hospitals that purchase these treatments.

The earlier version was much narrower. It included 10 drugs. The new version therefore adds 15 drugs and covers two and a half times as many medicines. The change broadens the number of products potentially affected by the shift from upfront discounts to after-the-fact rebates.

The larger scope also raises the stakes of the legal challenge. More hospitals and drug purchases could face the cash-flow arrangement if the pilot takes effect. The AHA is arguing that the government did not adequately measure the costs hospitals would incur under that model. The article gives no dollar estimate for those costs.

Under the proposed model, hospitals would no longer receive the relevant drug discount at the time of purchase. They would first pay the market price, then apply for a rebate. That timing could create a cash-flow problem, especially when medicines are expensive or purchased frequently.

The key mechanism is a shift in financial risk. Hospitals would temporarily finance the full cost of drugs while waiting for the government process to return the discount. The AHA says the government did not accurately account for these costs. Hospitals used more than 2,400 comments to describe the expected effects in detail.

The article does not quantify the burden or say how quickly rebates would be paid. It does report that the lawsuit describes the potential impact as catastrophic. If the pilot begins on January 1, 2027, affected hospitals may need more working capital or face pressure on their operations while rebates remain pending.

The Health Resources and Services Administration, or HRSA, is the HHS division that administers the 340B program. It is the agency named in the lawsuit as having received comments about the proposed rebate model. HRSA therefore sits at the center of the program’s administration and public feedback process.

The Department of Health and Human Services is the federal department overseeing that division. The article says the agency announced the expanded version in February. The plan would change the way discounts work for 25 costly, widely used drugs covered under Medicare, subject to the ongoing legal challenge.

The division between the two roles matters. HRSA administers 340B, while HHS is the department associated with the broader policy action. The article does not describe every HHS responsibility or identify a specific official. It does establish that HHS previously withdrew the earlier plan after losing on appeal.

The AHA first sued over a more limited version of the rebate model in 2025. A judge agreed to temporarily halt that plan before it took effect. The ruling stopped the government from immediately implementing the earlier approach while the legal dispute continued.

The government then lost on appeal. After that loss, the Health and Human Services Department voluntarily withdrew the plan. The article presents this withdrawal as the outcome of the first legal challenge, not as a permanent end to the policy idea.

In February, the agency announced an expanded version. It would begin January 1, 2027, and cover 25 costly, widely used Medicare drugs instead of the original 10. The AHA has now filed a second lawsuit, repeating its argument that officials did not properly measure hospitals’ costs under an after-the-fact rebate system.

Drug discounts matter because medicine prices are not handled the same way by every organization. A reduced price can lower a provider’s immediate spending and free resources for patient care. Rebates can also create savings, but they arrive later and require the buyer to finance the purchase first.

The 340B dispute shows why the difference matters. Under the proposed model, hospitals would pay market prices for selected drugs and then apply for rebates. The AHA argues that this process would impose costs the government failed to calculate accurately. Hospitals described the potential impact in more than 2,400 comments submitted to HRSA.

The article does not compare specific prices among organizations or quantify the broader health system’s savings. It does show that payment design can shift financial risk between government programs, drug purchasers, and providers. The expanded pilot would test that shift for 25 Medicare drugs beginning January 1, 2027, if the lawsuit does not stop it.